Lonza’s Synaffix adds Boehringer and Mitsubishi Tanabe as ADC licensing partnersnews2025-01-09T13:00:07+00:00January 9th, 2025|Endpoints News|
Resilience cuts 120 employees at a former bluebird gene therapy sitenews2025-01-08T16:16:38+00:00January 8th, 2025|Endpoints News|
BWX Technologies to buy Canadian isotope maker for $525Mnews2025-01-07T16:30:28+00:00January 7th, 2025|Endpoints News|
Anthem Biosciences eyes $397M public offering in Indianews2025-01-06T18:10:27+00:00January 6th, 2025|Endpoints News|
WuXi Biologics to sell Irish vaccine site to Merck for $500Mnews2025-01-06T16:58:02+00:00January 6th, 2025|Endpoints News|
WuXi AppTec sells cell and gene therapy business to investornews2024-12-26T16:25:08+00:00December 26th, 2024|Endpoints News|
Lonza expands capsule footprint; BioCentriq’s new HQnews2024-12-19T15:15:21+00:00December 19th, 2024|Endpoints News|
FDA rejects J&J’s subcutaneous Rybrevant over manufacturing issuesnews2024-12-17T12:05:04+00:00December 17th, 2024|Endpoints News|
Novo Nordisk to spend $1.2B for new rare disease drug factory in Denmarknews2024-12-16T12:00:19+00:00December 16th, 2024|Endpoints News|
FTC OKs Novo-Catalent deal, in major win for Novo Nordisk’s GLP-1 manufacturingnews2024-12-14T10:42:12+00:00December 14th, 2024|Endpoints News|
